

Complement-human histocompatibility antigen haplotypes in C2 deficiency.

Z L Awdeh, ... , E Yunis, C A Alper

J Clin Invest. 1981;**67**(2):581-583. <https://doi.org/10.1172/JCI110070>.

Research Article

C4 allotyping 13 homozygous C2-deficient individuals demonstrated 23 of 25 haplotypes to be of the relatively rare type C4A4 B2. This is of the same magnitude as the association of C2Q0 with HLA-DW2/DR2.

Find the latest version:

<https://jci.me/110070/pdf>



Complement-Human Histocompatibility Antigen Haplotypes in C2 Deficiency

ZUHEIR L. AWDEH, DONALD D. RAUM, DAVID GLASS, VINCENT AGNELLO, PETER H. SCHUR, RICHARD B. JOHNSTON, JR., ERWIN W. GELFAND, MARK BALLOW, EDMOND YUNIS, and CHESTER A. ALPER, *Center for Blood Research, The Brigham and Women's Hospital, Sidney Farber Cancer Institute, Boston, Massachusetts 02115; New England Medical Center, Boston, Massachusetts 02111; University of Alabama Medical School, Birmingham, Alabama; Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada; University of Connecticut Health Center, Farmington, Connecticut 06032; and National Jewish Hospital, Denver, Colorado 80206*

ABSTRACT C4 allotyping 13 homozygous C2-deficient individuals demonstrated 23 of 25 haplotypes to be of the relatively rare type $C4A^*4 B^*2$. This is of the same magnitude as the association of $C2^*Q0$ with $HLA-DW2/DR2$.

INTRODUCTION

Deficiency of the second component of complement ($C2^*Q0$) has been extensively studied and reported and has a gene frequency near 1% (K. Stratton. Personal communication.). $C2^*Q0$ is known to be *HLA*-linked (1-4) and to be a silent allele at the C2 structural locus (5). The structural locus for C2 is also known to be linked to the *HLA* region (6-10). The structural polymorphism of the fourth component of human complement (C4) has been shown to be caused by two closely linked loci, associated with Rodgers and Chido positivity (11-13). Deficiency of one or the other of these proteins is relatively common, whereas the haplotype deficient for both is very uncommon. By desialation before electrophoresis and subsequent crossed immunoelectrophoresis, it is possible to detect individuals heterozygous for these partial deficiencies (14).

Using desialated plasma, prolonged agarose gel electrophoresis, and immunofixation, six common structural variants at the Rodgers locus and two common variants at the Chido locus have been defined (15). The nomenclature used by us to describe the genetic variants of C4 is the same as that proposed earlier (15). The alleles of the acidic, Rodgers-positive, [Rg(a+)], C4 alleles are designed $C4A^*1-6$ and those for the basic, Chido-positive, [Ch(a+)] alleles $C4B^*1,2$. There is a null allele at each locus designated $C4A^*Q0$ and $C4B^*Q0$. The linkage of a C4 structural locus to *HLA* was first inferred from the study of two C4-deficient families (16-18). The model of O'Neill et al. (11, 12) also postulates linkage to *HLA* of the two closely linked C4 loci. The red cell antigens Rodgers and Chido carried on C4 have been independently shown to be *HLA* linked (19-21). The structural polymorphism of C4 has also been shown to be linked to C2 and BF (15), and no crossovers have been observed among these loci. Properdin factor B (BF)¹ of the alternative pathway of complement activation also exhibits a common polymorphism with two common, BF^*F and BF^*S , and two rarer alleles, BF^*F1 and BF^*S1 (22). The structural locus for BF is closely

Received for publication 13 October 1980 and in revised form 12 November 1980.

¹ Abbreviation used in this paper: BF, properdin factor B.

linked to *HLA* in man (23). No crossover has yet been observed between *C2*Q0* and *BF* (24) or *C2* and *BF* (10). Finally, the loci for *C2*, *BF*, *C4A*, and *C4B* are thought to be close to *HLA-D* and *HLA-DR* with no observed recombination between them (25).

The present report concerns the haplotypes of *HLA*, *BF*, and *C4* alleles associated with *C2*Q0* in 13 homozygous *C2*-deficient individuals.

METHODS

The 13 subjects in this study are all homozygous *C2*-deficient individuals. They were unrelated except that K.R.T. is the daughter of G.R. Blood was collected into EDTA, and plasma was separated, stored at -80°C , and thawed just before analysis. For *BF* typing, samples were subjected to agarose gel electrophoresis and immunofixation with goat antiserum to human factor B (22). Plasma samples were desialated by incubation with neuraminidase from *Clostridium perfringens* (Type VI, Sigma Chemical Co., St. Louis, Mo.) at a concentration of 10 mU enzyme/ μl of plasma for 15 h at 4°C while dialyzed against 0.1 M phosphate buffer, pH 6.8 containing 0.005 M Na_2EDTA . For the detection of *C4* half-null haplotypes, desialated plasma samples were subjected to crossed immunoelectrophoresis as described previously (14). *C4* structural variants were detected by electrophoresis of desialated plasma in agarose gel (ICN Nutritional Biochemicals, Cleveland, Ohio) and immunofixation with goat anti-human *C4* antiserum (Atlantic Antibodies, Scarborough, Me.) as described previously (15). Homozygous *C2* deficiency was determined by previously published methods (4, 24, 26-28).

RESULTS

Of the 13 homozygous *C2*-deficient individuals tested for *C4*, 11 were apparent homozygotes at both *C4* loci and had a *C4* type of *C4A* 4, *C4B* 2 and were presumably of genotype *C4A*4,C4B*2/C4A*4,C4B*2*. The two exceptions were a man and his daughter. The man was homozygous deficient at the *C4B* locus, heterozygous

at the *C4A* locus, had a *C4* type of *C4A* 3,4, *C4B* Q0, and was therefore of the genotype *C4A*4,C4B*Q0/C4A*3,C4B*Q0*. His daughter had inherited *C4A*4,C4B*2* in linkage with *C2*Q0* from her mother and *C4A*4,C4B*Q0* from her father. The *C4*, *BF*, and *HLA* types of these deficient subjects are given in Table I. *C2*Q0* has a gene frequency of about 1%, and *C4A*4,B*2* has a haplotype frequency of about 6.5%, whereas *HLA-DW2* has a frequency of about 8%. From Table I, it is seen that 23 of 25 independent *C2*Q0* haplotypes were *C4A*4,C4B*2*, and 24 of 25 were *C4A*4*.

DISCUSSION

All cases for which information on *C2* deficiency have been available are Caucasians. In contrast, the majority of patients with complement deficiencies of late-acting components have been Negroes. It has been calculated from a review of the literature (29) that *C2* deficiency (*C2*Q0*) is in linkage disequilibrium with *HLA-B18* on approximately 56% of chromosomes but with *HLA-DW2* on about 94% of chromosomes. The linkage disequilibrium reported here between *C2*Q0* and *C4A*4,C4B*2* is of the same order of magnitude as that between *HLA-DW2* and *C2*Q0* suggesting that the loci for the complement components *C4A*, *C4B*, *BF*, and *C2* are closer to *HLA-D* and *DR* than to *HLA-B*. If one assumes that the mutation giving rise to *C2* deficiency occurred only once on a chromosome that was *HLA-A10,B18,DW2,DRW2,C4A*4,C4B*2,BF*S*, then the current and previous findings suggest that the *C2* locus is very close to *BF* and the two *C4* loci, *C4A* and *C4B*. The haplotype *C4A*4,B*Q0* has been observed only this once among all individuals studied to the present (more than 300 normal haplotypes). This makes it most likely that this haplotype arose either by deletion from *C4A*4,C4B*2* or by a crossover between

TABLE I
Chromosome Six Markers In *C2*-deficient Individuals

Patient	BF	HLA	C4 Haplotype	Reference
A.W.	S/S	A10,B18/A1,B8	A4,B2/A4,B2	(27)
S.S.	S/S	A3,B18,DR2/A10,B14	A4,B2/A4,B2	
M.C.	S/S	—	A4,B2/A4,B2	
A.O.	S/S	—	A4,B2/A4,B2	
E.M.	S/S	A2,B18,DR2/A26(10),B12	A4,B2/A4,B2	
G.R.	S/S	A10,B18/A10,B18	A4,BQ0/A3,BQ0*	
L.M.	S/S	A25(10),B18,DR3,GLO2/A2,B18,DR2,GLO 1	A4,B2/A4,B2	(28)
A.B.	S/S	—	A4,B2/A4,B2	
B.S.	S/S	—	A4,B2/A4,B2	
L.Sh.	S/S	A10,B18,DW2/A10,B18,DW2	A4,B2/A4,B2	(1, 26)
L.So.	S/S	—	A4,B2/A4,B2	
K.R.T.	S/S	—	A4,B2/A4,BQ0*	
A.F.	S/S	A25,B18,DW2/A25,B18,DW2	A4,B2/A4,B2	

* Related individuals G.R. and K.R.T.

C4A*4 and C4B*2 with a C4B*Q0 being substituted. This suggests that C4A is closer to C2 than is C4B. Similarly, the presumed substitution in the past of HLA-DR3 for HLA-DR2 in individual L.M. is consistent with the possibility that the complement genes are located between HLA-B and HLA-DR.

ACKNOWLEDGMENT

We thank Debbie Marcus and Sharon Karp for technical assistance.

This work was supported by National Institutes of Health grants AI 14157, AI 15033, AM 16392, AM11414, AM05577, AM00449, AI-14148, CA19589 and CA20531; The American Red Cross; and the New England Peabody Foundation.

REFERENCES

1. Fu, S. M., H. G. Kunkel, H. P. Brusman, F. H. Allen, Jr., and M. Fotino. 1974. Evidence for linkage between HL-A histocompatibility genes and those involved in the synthesis of the second component of complement. *J. Exp. Med.* **140**: 1108–1111.
2. Day, N. K., P. L'Esperance, R. A. Good, A. F. Michael, J. A. Hansen, B. Dupont, and C. Jersild. 1975. Hereditary C2 deficiency: genetic studies and association with the HL-A system. *J. Exp. Med.* **141**: 1464–1469.
3. Wolski, K. P., F. R. Schmid, and K. L. Mittal. 1975. Genetic linkage between HL-A system and a deficit of the second component (C2) of complement. *Science (Wash. D. C.)*. **188**: 1020–1022.
4. Glass, D., D. Raum, D. Gibson, J. A. Stillman, and P. H. Schur. 1976. Inherited deficiency of the second component of complement: rheumatic disease associations. *J. Clin. Invest.* **58**: 853–861.
5. Pariser, K. M., D. Raum, E. M. Berkman, C. A. Alper, and V. Agnello. 1978. Evidence for a silent or null gene in hereditary C2 deficiency. *J. Immunol.* **121**: 2580–2581.
6. Alper, C. A. 1976. Inherited structural polymorphism in human C2: evidence for genetic linkage between C2 and Bf. *J. Exp. Med.* **144**: 1111–1115.
7. Hobart, M. J., and P. J. Lachmann. 1976. Allotypes of complement components in man. *Transplant. Rev.* **32**: 26–42.
8. Meo, T., J. P. Atkinson, M. Bernoco, D. Bernoco, and R. Ceppellini. 1977. Structural heterogeneity of C2 complement protein and its genetic variants in man: a new polymorphism of the HLA region. *Proc. Natl. Acad. Sci. U. S. A.* **74**: 1672–1675.
9. Olaisen, B., P. Teisberg, T. Gedde-Dahl, Jr., and E. Thorsby. 1978. Genetic polymorphism of the second component of human complement (C2). *Hum. Genet.* **42**: 301–305.
10. Raum, D., D. Glass, C. B. Carpenter, P. H. Schur, and C. A. Alper. 1979. Mapping of the structural gene of the second component of complement with respect to the human major histocompatibility complex. *Am. J. Hum. Genet.* **31**: 35–41.
11. O'Neill, G. J., S. Y. Yang, and B. Dupont. 1978. Two HLA-linked loci controlling the fourth component of human complement. *Proc. Natl. Acad. Sci. U. S. A.* **75**: 5165–5169.
12. O'Neill, G. J., S. Y. Yang, J. Tegoli, R. Berger, and B. Dupont. 1978. Chido and Rodgers blood groups are distinct antigenic components of human complement C4. *Nature (Lond.)*. **273**: 668–670.
13. O'Neill, G. J., and B. Dupont. 1979. Serum C4 levels, Chido, Rodgers, and allotypes of C4 component of complement. *Transplant. Proc.* **11**: 1102–1106.
14. Awdeh, Z. L., D. Raum, and C. A. Alper. 1979. Genetic polymorphism of human complement C4 and detection of heterozygotes. *Nature (Lond.)*. **282**: 205–207.
15. Awdeh, Z. L., and C. A. Alper. 1980. Inherited structural polymorphism of the fourth component of complement. *Proc. Natl. Acad. Sci. U. S. A.* **77**: 3576–3580.
16. Hauptmann, G., E. Grosshans, E. Heid, S. Mayer, and A. Basset. 1974. Lupus érythémateux aigu avec déficit complet de la fraction C4 du complément. *Nouv. Presse Med.* **3**: 881–882.
17. Rittner, C., G. Hauptmann, H. Grosse-Wilde, E. Grosshans, M. M. Tongio, and S. Mayer. 1975. Linkage between HL-A (major histocompatibility complex) and genes controlling the synthesis of the fourth component of complement. In *Histocompatibility Testing*, F. Kissmeyer-Nielsen editor. International Booksellers & Publishers, Copenhagen. Munksgaard, 945–954.
18. Ochs, H. D., S. I. Rosenfeld, E. D. Thomas, E. R. Giblett, C. A. Alper, B. Dupont, J. G. Schaller, B. C. Gilliland, J. A. Hansen, and R. J. Wedgwood. 1977. Linkage between the gene (or genes) controlling synthesis of the fourth component of complement and the major histocompatibility complex. *N. Engl. J. Med.* **296**: 470–475.
19. Middleton, J., M. C. Crookston, J. A. Falk, E. B. Robson, P. J. L. Cook, J. R. Batchelor, J. Bodmer, G. B. Ferrara, H. Festenstein, R. Harris, F. Kissmeyer-Nielsen, S. D. Lawler, J. A. Sachs, and E. Wolf. 1974. Linkage of Chido and HLA. *Tissue Antigens.* **4**: 366–373.
20. James, J., P. Stiles, F. Boyce, and J. Wright. 1976. The HL-A type of Rg (a-) individuals. *Vox Sang.* **30**: 214–216.
21. Giles, C. M., T. Gedde-Dahl, Jr., E. B. Robson, E. Thorsby, B. Olaisen, A. Arnason, F. Kissmeyer-Nielsen, and I. Schreuder. 1976. Rg^a (Rodgers) and the HLA region: linkage and association. *Tissue Antigens.* **8**: 143–149.
22. Alper, C. A., T. Boenisch, and L. Watson. 1972. Genetic polymorphism in human glycine-rich beta-glycoprotein. *J. Exp. Med.* **135**: 68–80.
23. Allen, F. H., Jr. 1974. Linkage of HL-A and GBG. *Vox Sang.* **27**: 382–384.
24. Raum, D., D. Glass, C. B. Carpenter, C. A. Alper, and P. H. Schur. 1976. The chromosomal order of genes controlling the major histocompatibility complex, properdin Factor B, and deficiency of the second component of complement. *J. Clin. Invest.* **58**: 1240–1248.
25. Raum, D., Z. L. Awdeh, D. Glass, E. Yunis, and C. A. Alper. The location of C2, C4, and BF relative to HLA-B and HLA-D. *Immunogenetics*. In press.
26. Fu, S. M., R. Stern, H. G. Kunkel, B. Dupont, J. A. Hansen, N. K. Day, R. A. Good, C. Jersild, and M. Fotino. 1975. Mixed lymphocyte culture determinants and C2 deficiency in four families. *J. Exp. Med.* **142**: 495–506.
27. Gibson, D. J., D. Glass, C. B. Carpenter, and P. H. Schur. 1975. Hereditary C2 deficiency: diagnosis and HLA gene complex associations. *J. Immunol.* **116**: 1065–1070.
28. Einstein, L. P., C. A. Alper, K. J. Bloch, J. T. Herrin, F. S. Rosen, J. R. David, and H. R. Colten. 1975. Biosynthetic defect in monocytes from human beings with genetic deficiency of the second component of complement. *N. Engl. J. Med.* **292**: 1169–1171.
29. Agnello, V. 1978. Complement deficiency states. *Medicine (Baltimore)*. **57**: 1–24.